-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent reports Phase Ib asthma trial data for IBI3002 IL-4Rα/TSLP antibody

PUBT·05/19/2026 00:00:45
Listen to the news
Innovent reports Phase Ib asthma trial data for IBI3002 IL-4Rα/TSLP antibody
  • Innovent Biologics will present clinical Phase Ib results for its IBI3002 bispecific asthma antibody at the American Thoracic Society meeting on May 17-20, 2026.
  • The single-dose study in mild-to-moderate asthma showed favorable safety and tolerability, with signals of improved lung function and reduced markers linked to type 2 airway inflammation versus placebo.
  • Preclinical data for two other bispecific programs, IBI3038 for fibrosis-related autoimmune disease and IBI3031 for thyroid eye disease, were presented at ATS and ARVO in May 2026, supporting plans to move both candidates into clinical development later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605182000PR_NEWS_USPR_____CN61700) on May 19, 2026, and is solely responsible for the information contained therein.